Iqbal J. Hussain Sells 6,000 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) General Counsel Iqbal J. Hussain sold 6,000 shares of the business’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $16.45, for a total transaction of $98,700.00. Following the sale, the general counsel now directly owns 105,386 shares of the company’s stock, valued at approximately $1,733,599.70. The trade was a 5.39 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Centessa Pharmaceuticals Stock Performance

NASDAQ CNTA opened at $15.75 on Friday. The firm has a market cap of $2.08 billion, a price-to-earnings ratio of -10.29 and a beta of 1.54. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The business has a 50-day moving average price of $16.47 and a 200-day moving average price of $16.38. Centessa Pharmaceuticals plc has a twelve month low of $7.75 and a twelve month high of $19.09.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CNTA. Atria Investments Inc boosted its stake in Centessa Pharmaceuticals by 7.0% in the 3rd quarter. Atria Investments Inc now owns 17,134 shares of the company’s stock worth $274,000 after purchasing an additional 1,116 shares during the period. The Manufacturers Life Insurance Company boosted its position in shares of Centessa Pharmaceuticals by 88.1% during the third quarter. The Manufacturers Life Insurance Company now owns 264,969 shares of the company’s stock worth $4,237,000 after acquiring an additional 124,075 shares during the last quarter. FMR LLC boosted its position in shares of Centessa Pharmaceuticals by 4.6% during the third quarter. FMR LLC now owns 2,916,494 shares of the company’s stock worth $46,635,000 after acquiring an additional 129,300 shares during the last quarter. Ally Bridge Group NY LLC bought a new position in shares of Centessa Pharmaceuticals during the 3rd quarter valued at about $4,951,000. Finally, Suvretta Capital Management LLC bought a new position in shares of Centessa Pharmaceuticals during the 3rd quarter valued at about $1,119,000. 82.01% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

CNTA has been the subject of several recent research reports. TD Cowen initiated coverage on Centessa Pharmaceuticals in a report on Tuesday, January 7th. They set a “buy” rating for the company. Morgan Stanley reiterated an “overweight” rating and set a $27.00 price objective on shares of Centessa Pharmaceuticals in a research note on Friday, March 7th. Finally, Guggenheim reiterated a “buy” rating on shares of Centessa Pharmaceuticals in a research note on Monday, February 10th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $26.00.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.